Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Industry-Academia Cooperation Essential for Practical Use of iPS Cells
April 21, 2008
- COMMENTARY／Improvement of Drug Distribution Business Practices Goes into Crucial Stretch
April 14, 2008
- COMMENTARY／Mr Kodama Owes His Sweeping Victory to Members' Desire for Change: JPA
March 31, 2008
- COMMENTARY／Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
- Methodologic Issues in the Clinical Trial Study of Depression
March 24, 2008
- COMMENTARY／Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
March 3, 2008
- COMMENTARY／Preparations for New OTC Drug Marketing System Enter Final Stage
March 3, 2008
- COMMENTARY／Japan Needs to Create Attractive "Stadium for Drug Discovery" and Invite Top-Level Players
February 25, 2008
- COMMENTARY／Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry（2）
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry（1）
February 11, 2008
- COMMENTARY／Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes？
February 4, 2008
- COMMENTARY／Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- OPINION／The East versus West Dilemma
January 28, 2008
- COMMENTARY／Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- No More Need for MRs？ -A Hell beyond the 2010 Crisis？-
January 14, 2008
- COMMENTARY／Year 2007 in Retrospect
December 24, 2007
- COMMENTARY／Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
- COMMENTARY／Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
- COMMENTARY：Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…